NASDAQ : VOGX
Vogenx, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 20.25 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 300.82M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Selling, General & Admin | 913.84K | 867.15K | 984.31K |
| Research & Development | 660.96K | 571.97K | 1.32M |
| Operating Expenses | 1.57M | 1.44M | 2.30M |
| Operating Income | -1.57M | -1.44M | -2.30M |
| Interest & Investment Income | 1.63K | 6.03K | 39.21K |
| Other Non Operating Income (Expenses) | -80.90K | -12.52K | 58.03K |
| Pretax Income | -1.65M | -1.45M | -2.20M |
| Net Income | -1.65M | -1.45M | -2.20M |
| Net Income to Common | -1.65M | -1.45M | -2.20M |
| Shares Outstanding (Basic) | 5.45M | 5.45M | 5.45M |
| Shares Outstanding (Diluted) | 5.45M | 5.45M | 5.45M |
| EPS (Basic) | -0.30 | -0.27 | -0.40 |
| EPS (Diluted) | -0.30 | -0.27 | -0.40 |
| EBIT | -1.57M | -1.44M | -2.30M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 193.02K | 601.01K | 962.92K |
| Cash & Short-Term Investments | 193.02K | 601.01K | 962.92K |
| Prepaid Expenses | 11.38K | 16.80K | 7.47K |
| Other Current Assets | 1.20M | 63.36K | |
| Total Current Assets | 1.41M | 681.17K | 970.40K |
| Total Assets | 1.41M | 681.17K | 970.40K |
| Accounts Payable | 1.22M | 62.96K | 109.21K |
| Accrued Expenses | 1.10M | 709.82K | 286.50K |
| Short-Term Debt | 867.70K | 816.30K | |
| Total Current Liabilities | 3.19M | 1.59M | 395.71K |
| Other Long-Term Liabilities | 11.32K | 65.11K | |
| Total Liabilities | 3.19M | 1.60M | 460.81K |
| Common Stock | 526.00 | 1.58K | 1.58K |
| Additional Paid-In Capital | 9.92M | 9.92M | 9.90M |
| Retained Earnings | -11.70M | -10.84M | -9.40M |
| Total Common Equity | -1.78M | -919.80K | 509.02K |
| Shareholders' Equity | -1.78M | -919.24K | 509.58K |
| Total Liabilities & Equity | 1.41M | 681.17K | 970.40K |
| Total Debt | 867.70K | 816.30K | |
| Net Cash (Debt) | -674.68K | -215.29K | 962.92K |
| Net Cash Per Share | -0.12 | -0.04 | 0.18 |
| Filing Date Shares Outstanding | 14.86M | 5.26M | 5.45M |
| Total Common Shares Outstanding | 5.26M | 5.26M | 5.45M |
| Working Capital | -1.78M | -907.91K | 574.69K |
| Book Value Per Share | -0.34 | -0.17 | 0.09 |
| Tangible Book Value | -1.78M | -919.80K | 509.02K |
| Tangible Book Value Per Share | -0.34 | -0.17 | 0.09 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -1.65M | -1.45M | -2.20M |
| Stock-Based Compensation | 11.36K | 16.78K | 87.30K |
| Other Operating Activities | 80.90K | 12.52K | -58.03K |
| Change in Accounts Payable | 97.33K | -46.24K | -229.18K |
| Change in Other Net Operating Assets | 602.10K | 350.63K | 62.13K |
| Operating Cash Flow | -862.38K | -1.11M | -2.34M |
| Issuance of Common Stock | 750.00K | 750.00K | |
| Financing Cash Flow | 665.13K | 750.00K | |
| Net Cash Flow | -197.26K | -361.91K | -2.34M |
| Levered Free Cash Flow | -578.27K | ||
| Unlevered Free Cash Flow | -578.27K | ||
| Change in Working Capital | 699.43K | 304.39K | -167.05K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 300.82M | ||
| Enterprise Value | 301.49M | ||
| Debt / Equity Ratio | -0.49 | -0.89 | |
| Net Debt / Equity Ratio | -0.38 | -0.23 | -1.89 |
| Quick Ratio | 0.06 | 0.38 | 2.43 |
| Current Ratio | 0.44 | 0.43 | 2.45 |
| Return on Assets (ROA) | -108.92% | ||
| Return on Capital Employed (ROCE) | 88.50% | 158.50% | -400.40% |